What Sativex Treats: Main Uses and Benefits

The primary therapeutic role of Sativex (nabiximols) is to provide symptomatic support for moderate to severe muscle spasticity in adult patients with Multiple Sclerosis (MS). It is generally applied when symptoms are considered resistant to conventional therapies. The medication is applied across domains where additional symptomatic support is needed, addressing specific symptom clusters: muscle stiffness, involuntary spasms, and associated chronic pain.

This agent is used for managing symptoms of increased neurological or muscular activity, supporting the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort. “It is relevant in clinical settings where supportive symptom management is appropriate and symptoms are more noticeable.” Beyond the core motor dysfunction, the treatment assists in managing associated symptoms like impaired sleep quality, which are symptoms that interfere with daily functioning. A key therapeutic goal is supporting functional mobility and helping patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for MS Spasticity

Symptom Domain	General Therapeutic Benefit	Context of Use
Muscle Stiffness & Spasms	Eases overall symptom burden	Adjunctive use when symptoms are resistant to treatment
Chronic Pain	Contributes to improved comfort	Managing persistent spasticity-related discomfort
Sleep Impairment	Supports functional stability	Addressing symptoms that interfere with routine activities

Regulatory References

1. Australian Therapeutic Goods Administration (TGA) Public Assessment

Sativex is officially indicated for adult patients (18 years and older) with moderate to severe spasticity due to multiple sclerosis (MS). Eligibility requires that patients have not responded adequately to other anti-spasticity medications and demonstrate a clinically significant improvement during an initial four-week trial of therapy.

Contraindicated Populations

Official regulatory documents state that Sativex is contraindicated and must not be used by patients with:

• Hypersensitivity or allergy to cannabinoids (nabiximols) or any of the product's excipients.
• Any known or suspected history or family history of schizophrenia, other psychotic illness, or severe personality disorder (excluding MS-related depression).
• Women who are breastfeeding.

Restricted and Special Consideration Groups

• Age: Use is not recommended for children and adolescents under 18 due to insufficient safety and efficacy data.
• Pregnancy: Use during pregnancy is not recommended unless the potential benefit justifies the risks; women of childbearing potential must use reliable contraception during treatment and for three months afterward.
• Cardiovascular Conditions: Use is not recommended in patients with serious cardiovascular disease.
• Organ Function: Patients with significant impaired hepatic or renal function, or a history of epilepsy or recurrent seizures, require caution and frequent clinical evaluation.

Sativex (nabiximols) can interact with various other medicines and substances, potentially changing their effects or increasing the risk of side effects. It is crucial to inform your doctor or pharmacist about all medications, vitamins, supplements, and herbal remedies you are taking.

Increased Sedation and Dizziness

Co-administration with other central nervous system (CNS) depressants may increase feelings of drowsiness, dizziness, or impair your ability to react quickly. This includes:

Type of Medicine	Examples	Potential Risk
Muscle Relaxants	Baclofen, Diazepam	Increased risk of falls
Sedatives/Hypnotics	Benzodiazepines, Zopiclone	Excessive sedation
Alcohol	Ethanol	Potentiated effects, impaired coordination

Altered Metabolism of Sativex or Concomitant Drugs

Sativex is metabolized by the Cytochrome P450 (CYP) enzyme system. Therefore, medications that affect this system can change the concentration of Sativex components in your blood. This may necessitate a dosage adjustment for Sativex or the interacting drug.

• CYP3A4 Inhibitors: Drugs like ketoconazole, itraconazole (antifungals), and ritonavir (antiviral) may increase Sativex levels, raising the risk of side effects.
• CYP3A4 Inducers: Drugs like rifampicin (antibiotic), carbamazepine, or phenytoin (antiepileptics) may decrease Sativex levels, potentially reducing its effectiveness.

Other Important Interactions

Sativex may reduce the effectiveness of systemically acting hormonal contraceptives (e.g., birth control pills or implants). Patients using these methods should be advised to use an additional reliable barrier method of birth control throughout treatment and for at least three months after stopping Sativex.

The Mechanism of Sativex

Sativex is a botanical cannabinoid product containing the phytocannabinoids delta-9-tetrahydrocannabinol (Delta^9-THC) and cannabidiol (CBD). Its mechanism of action is mediated primarily through interactions with the endocannabinoid system (ECS).

Delta^9-THC functions as a partial agonist at the cannabinoid receptor type 1 ( CB1) and type 2 ( CB2) receptors, which are G protein-coupled receptors ( G i/o-coupled). CB1 receptors are highly concentrated in the central nervous system (CNS) on presynaptic nerve terminals. Activation of CB1 receptors causes an inhibition of adenylate cyclase and modulates voltage-gated ion channels ( Ca^2+ and K^+). This CB1-mediated cascade leads to a reduction in the release of various excitatory and inhibitory neurotransmitters, thereby modulating synaptic transmission and neuronal excitability.

CBD displays a complex pharmacology, exhibiting low affinity for CB1 and CB2 receptors but acting as a non-competitive antagonist of CB1 receptor agonists. Additionally, CBD interacts with multiple non-cannabinoid targets, including the serotonin 5- HT1 A receptor (as an agonist) and transient receptor potential ( TRP) ion channels. This dual-constituent mechanism results in modulation of spinal excitability and intracortical inhibition, influencing downstream physiological signaling.

How Sativex is Used: Official Administration Guidelines

Sativex (nabiximols) is exclusively administered as an oromucosal spray onto the lining of the mouth, most often inside the cheek or under the tongue. The fixed-dose spray delivers 2.7 mg of Delta-9-THC and 2.5 mg of Cannabidiol (CBD) per actuation. The use protocol is defined by a mandatory, patient-specific titration schedule and fixed limits on daily intake.

---

Dosing and Schedule

Treatment must begin with a slow, gradual titration period, typically lasting up to two weeks, to determine the optimal dose that provides relief with acceptable tolerability. Doses are divided between the day, and a minimum interval of 15 minutes must be maintained between subsequent sprays. The official maximum recommended dose is 12 sprays per day.

Administration and Procedural Rules

Procedural Requirement	Official Instruction Summary
Route & Preparation	Spray directly onto the oral mucosa; the container must be shaken before use and primed before the first use.
Application Site	The spray must be directed at different sites in the mouth to avoid irritation, alternating the site for each spray.
Food Relationship	Administration should be standardized in relation to food intake to minimize variations in absorption.
Trial Period	The prescription requires a four-week trial period, after which a physician must formally assess whether clinically significant improvement has been achieved for treatment to continue.
Age Restrictions	Use is not recommended for patients under 18 years of age due to insufficient data.

These instructions define the standardized, procedural steps necessary for the correct intake of the medication as established by official clinical guidelines.

Research Evidence / Overview of Studies for Sativex

The research evidence for Sativex (Nabiximols) focuses on its evaluation through official, controlled clinical trials and observational studies, primarily concerning muscle stiffness that has not responded well to other conventional treatments. The evidence base includes a focus on understanding how symptoms change over time and what outcomes are measured in specific patient groups.

---

Evidence for Use in Multiple Sclerosis (MS) Spasticity

This section will summarize the structure of the clinical evidence supporting the clinical situation that was studied, including findings from short-term Randomized Controlled Trials (RCTs) and subsequent long-term follow-up studies. It will detail how researchers measured changes in patient-reported spasticity, spasm frequency, and related symptoms in adult patients with MS.

The research base includes Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and applied in research contexts involving fluctuating or unstable symptoms. The trials primarily focused on adult patients with MS whose moderate-to-severe muscle spasticity was considered resistant to standard medications. Research examined patient-reported outcomes describing perceived discomfort related to physical discomfort, using a standard numerical rating scale (NRS).

The studies reported how symptoms evolved in the observed populations over defined time intervals, typically ranging from 6 to 15 weeks. Research explored how many participants met a pre-defined threshold in their reported spasticity score, a finding that describes patterns observed in the studies. However, when researchers analyzed the mean overall change in spasticity across all participants in some trials, the findings varied. Data show patterns primarily related to patient-reported changes.

What remains uncertain is the full characterization of long-term effects. Long-term outcomes are not fully established because the most rigorous, placebo-controlled data were collected over short follow-up durations. Information about how symptom patterns persist over time beyond several months relies largely on less controlled open-label extension studies. Additionally, results apply only to the populations studied, which were often filtered to include only patients who showed an initial short-term response, meaning research does not determine whether an individual who has not yet tried the agent will respond similarly.

---

Overview of Research in Refractory Cancer-Related Pain

This part of the overview will outline the research base for the agent's use as an adjunctive therapy for persistent, difficult-to-manage chronic pain in advanced cancer patients. It will describe the specialized study designs used and what specific pain and functional outcomes were examined in the trials.

Research explored the agent's use as an add-on therapy for adults with advanced cancer experiencing persistent chronic pain that was not wholly alleviated by maximized standard opioid treatment. Studies conducted during periods of increased symptom activity were designed as Randomized Controlled Trials (RCTs) over observation periods typically lasting around 5 to 9 weeks. The research examined outcomes related to physical discomfort, such as the change in the daily pain score (NRS), and also monitored physiological strain or stress, such as sleep quality.

Findings describe patterns observed in the studies, where some trials reported measurements of a change in the patient-reported pain score for certain subgroups. However, the available data for this indication remain limited and heterogeneous. Some key trials reported findings that varied, and therefore certainty remains low across the entire body of evidence for all cancer pain types.

Key Studies & References

1. NICE Guideline NG144: Multiple sclerosis: management of spasticity and treatment with THC:CBD spray (Sativex)
2. AusPAR: Nabiximols (Australian Public Assessment Report - TGA)

Common questions about Sativex (FAQ)

Q: How quickly should someone notice the effects after using Sativex?

Studies on how the body processes the medicine indicate that the maximum concentration of the main active component, Delta-9-THC, is typically reached in the bloodstream between 45 to 120 minutes (1 to 2 hours) after a single dose administration. This pharmacokinetic information describes the timeframe for peak blood levels after using the oromucosal spray.

Q: Why is Sativex given as an oral spray and not a pill?

Sativex is specially formulated as an oromucosal spray intended for application onto the lining of the mouth. This route of administration is designed to allow the active components to be systemically absorbed (into the bloodstream) more directly. Official guidelines state that administration should be standardized in relation to food intake to minimize variations in this absorption process.

Q: Are there any special considerations for older patients using Sativex?

Regulatory documents do not provide specific dose adjustments for elderly patients. However, caution is advised for any patient with impaired renal or hepatic function (kidney or liver problems), which may be more prevalent in older populations. The official requirements indicate that patients in these special consideration groups require careful clinical evaluation by a healthcare professional.

Q: Is Sativex considered a controlled substance?

Official product information notes that one of the active ingredients in Sativex has the potential for physical and psychological dependence and abuse. As a result, its specific legal classification is often regulated and categorized as a controlled substance, though its exact legal scheduling varies depending on a country's national drug control laws.

Q: Does Sativex lose its effectiveness over time (tolerance)?

Based on long-term clinical trials, there is no evidence of a consistent increase in the daily dosage being observed over time. The data indicate that no consistent increase in the daily dose was observed in long-term clinical use, which is a factor in assessing potential tolerance.

Q: Does Sativex interact with common antidepressants?

The metabolism of Sativex is handled by the body's CYP3A4 enzyme system. Therefore, official documents caution that certain antidepressants classified as strong CYP3A4 inhibitors or inducers may alter the concentration of Sativex in the bloodstream. This means they could potentially increase the risk of side effects or reduce the effectiveness of Sativex.

Q: Is it true that Sativex is not available in the United States?

Sativex is not approved by the U.S. Food and Drug Administration (FDA) for commercial prescription in the United States. It has been approved in other countries, including Canada and the United Kingdom.

Q: What should be done if an adverse reaction is suspected after using Sativex?

If a patient suspects they are experiencing a side effect, they are officially instructed to report the reaction to their doctor or pharmacist. Patients are also advised that adverse events can be reported directly to their country's national regulatory authority, which handles drug safety surveillance.

Q: How does Sativex's legal status vary between countries?

Official information advises patients that if they travel to another country, it is possible the medicine may not be legal to possess or use in that jurisdiction. The official warning recommends verifying the legal status of the medicine in the destination country prior to travel.

Q: What are the ingredients in Sativex other than the main active components?

Regulatory documents list several inactive components (excipients) in the product formulation. These include Propylene Glycol, Ethanol (alcohol), and a Peppermint flavor; some product monographs also list various other minor cannabinoids and terpenes from the extract.

Q: Does Sativex show up on standard drug tests?

Due to the presence of its active ingredient, Delta-9-THC, and its metabolites, the use of Sativex may result in a positive test for cannabinoids on standard drug screening tests.

Q: What is the general withdrawal experience described when stopping Sativex?

The abrupt withdrawal of long-term treatment has not resulted in a consistent pattern of withdrawal symptoms. Official documentation notes that if consequences occur, they are generally described as transient disturbances of sleep, emotion, or appetite in some patients.

Storage and Disposal Requirements

Sativex Oromucosal Spray has distinct storage requirements for its unopened and opened states, strictly following regulatory standards for stability.

Storage Conditions

Product State	Temperature Requirement	Additional Storage Rules
Unopened	Store in a refrigerator between 2°C and 8°C.	Must be stored upright in its original carton. Do not freeze.
Opened (In-Use)	Store at a temperature below 25°C.	Must be discarded 42 days (6 weeks) after first opening. Store upright.

Safety and Handling

The medicine must be kept out of the sight and reach of children. The container should be protected from heat and direct sunlight, and not used near flames. Unused or expired Sativex must not be thrown away in household waste or wastewater and should be disposed of in accordance with local regulatory requirements.